Imperial College London
Portrait Picture

DrAileenRowan

Faculty of Medicine, Department of Infectious Disease

Lecturer in Molecular Virology
 
 
 
//

Contact

 

+44 (0)20 7594 3916a.rowan

 
 
//

Location

 

VD4Wright Fleming WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Cook:2021:10.21037/aol-21-6,
author = {Cook, L and Rowan, A and Bangham, C},
doi = {10.21037/aol-21-6},
journal = {Annals of Lymphoma},
pages = {1--10},
title = {Adult T-cell leukemia/lymphoma—pathobiology and implications for modern clinical management},
url = {http://dx.doi.org/10.21037/aol-21-6},
volume = {5},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Adult T-cell leukemia/lymphoma (ATL) is a highly aggressive malignancy that arises in 2-5% of carriers of human T-cell lymphotropic virus type 1 (HTLV-1). The median overall survival of acute and lymphoma subtypes remains approximately 9–13 months and depressingly, with chemotherapy based approaches survival is largely unchanged in the ~40 years since it was first described. There is a clear and urgent need to conduct clinical trials of novel therapies in this disease. A high proviral load (PVL) (>4%, percentage of HTLV-1 infected mononuclear cells), male gender and smoking were previously the only major known risk factors for developing ATL, and so it has been difficult to advise patients about their individual risk of future ATL. Here, we describe the recent evidence that malignant disease does not occur randomly amongst all asymptomatic carriers but is more likely to arise in a subset of high PVL individuals with abnormally abundant clonal expansions of circulating HTLV-1 infected T-cells which typically express CD3dim+ CD4+ CD5-CD7- CD25+ CCR4+ with monoclonal TCRVβ. These clones also typically harbour known ATL driver mutations such as PLCG1, PRKCB, CARD11, STAT3, VAV1, NOTCH1, IRF4, CCR4, CCR7, TP53 and CDKN2, and may be detectable 10 years prior to disease presentation providing an opportunity to identify at risk individuals prior to clinical ATL. We describe the current classification and clinical features of ATL, and the exciting work of the last few years that underpins our new understanding of the genetic and epigenetic landscape with implications for future therapy. Whilst current therapy for aggressive ATL remain largely ineffective, recent advances may allow for early identification of at-risk individuals, and for pre-emptive therapies, and hope for a new era of effective targeted biological agents.
AU  - Cook,L
AU  - Rowan,A
AU  - Bangham,C
DO  - 10.21037/aol-21-6
EP  - 10
PY  - 2021///
SN  - 2616-2695
SP  - 1
TI  - Adult T-cell leukemia/lymphoma—pathobiology and implications for modern clinical management
T2  - Annals of Lymphoma
UR  - http://dx.doi.org/10.21037/aol-21-6
UR  - https://aol.amegroups.com/article/view/7306/html
UR  - http://hdl.handle.net/10044/1/100565
VL  - 5
ER  -
Download